Evidence map›Paper›PMID 29122991›Full record

ArticleHaematologica2018

Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.

Arnold Bolomsky, Roy Heusschen, Karin Schlangen, Kathrin Stangelberger, Joséphine Muller, Wolfgang Schreiner, Niklas Zojer, Jo Caers, Heinz Ludwig

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Arnold BolomskyWilhelminen Cancer Research Institute, Department of Medicine I, Wilhelminenspital, Vienna, Austria.
Roy HeusschenLaboratory of Hematology, GIGA-I3, University of Liège, Belgium.
Karin SchlangenCenter for Medical Statistics, Informatics and Intelligent Systems, Section for Biosimulation and Bioinformatics, Medical University of Vienna, Austria and.
Kathrin StangelbergerWilhelminen Cancer Research Institute, Department of Medicine I, Wilhelminenspital, Vienna, Austria.
Joséphine MullerLaboratory of Hematology, GIGA-I3, University of Liège, Belgium.
Wolfgang SchreinerCenter for Medical Statistics, Informatics and Intelligent Systems, Section for Biosimulation and Bioinformatics, Medical University of Vienna, Austria and.
Niklas ZojerWilhelminen Cancer Research Institute, Department of Medicine I, Wilhelminenspital, Vienna, Austria.
Jo CaersLaboratory of Hematology, GIGA-I3, University of Liège, Belgium heinz.ludwig@aon.at jo.caers@chu.ulg.ac.be.
Heinz LudwigWilhelminen Cancer Research Institute, Department of Medicine I, Wilhelminenspital, Vienna, Austria heinz.ludwig@aon.at jo.caers@chu.ulg.ac.be.
Wilhelminen Hospital · ATUniversity of Liège · BEMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of high-risk patients is a major challenge in multiple myeloma. This is especially true for patients assigned to the gene expression profiling-defined proliferation subgroup. Although recent efforts have identified some key players of proliferative myeloma, genetic interactions and players that can be targeted with clinically effective drugs have to be identified in order to overcome the poor prognosis of these patients. We therefore examined maternal embryonic leucine zipper kinase (MELK) for its implications in hyper-proliferative myeloma and analyzed the activity of the MELK inhibitor OTSSP167 both

Indexed as

AnimalsApoptosisCell CycleCell Line, TumorCell ProliferationHumansMiceMultiple MyelomaNaphthyridinesPrognosisProtein Serine-Threonine KinasesRisk Assessment1-(6-(3,5-dichloro-4-hydroxyphenyl)-4-((4-((dimethylamino)methyl)cyclohexyl)amino)-1,5-naphthyridin-3-yl)ethanoneMELK protein, humanNaphthyridinesProtein Serine-Threonine Kinases

Identifiers

PMID29122991
PMCPMC5792277
OpenAlexW2767793479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.